Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients

Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer

(2011) A. M. Gonzalez-Angulo et al.   CLINICAL CANCER RESEARCH

Evaluation of O6-methylguanine-DNA methyltransferase by immunohistochemistry: Best clinical and research practices

(2011) Julio Cirullo Neto et al.   PATHOLOGY RESEARCH AND PRACTICE

Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer

(2010) A. DeCensi et al.   ANNALS OF ONCOLOGY

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

(2010) L. Staudacher et al.   ANNALS OF ONCOLOGY

Triple-Negative Breast Cancer

(2010) Steven J. Isakoff   CANCER JOURNAL

MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC

(2010) Christian Busch et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients

(2010) Gayatri Sharma et al.   LIFE SCIENCES

Triple-negative breast cancer: disease entity or title of convenience?

(2010) Lisa Carey et al.   Nature Reviews Clinical Oncology

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

Defective Repair of Oxidative DNA Damage in Triple-Negative Breast Cancer Confers Sensitivity to Inhibition of Poly(ADP-Ribose) Polymerase

(2009) E. Alli et al.   CANCER RESEARCH

Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design

(2009) Farrah Kassam et al.   Clinical Breast Cancer

Genomic and Molecular Profiling Predicts Response to Temozolomide in Melanoma

(2009) C. K. Augustine et al.   CLINICAL CANCER RESEARCH

Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations

(2009) Jeung Il Kim et al.   HUMAN PATHOLOGY

Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide

(2009) Martin Glas et al.   JOURNAL OF CLINICAL ONCOLOGY

Platinum-based chemotherapy in triple-negative breast cancer

(2008) B. Sirohi et al.   ANNALS OF ONCOLOGY

Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer

(2008) Nancy U. Lin et al.   CANCER

Therapeutic Strategies for Triple-Negative Breast Cancer

(2008) Antoinette R. Tan et al.   CANCER JOURNAL

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

What is triple-negative breast cancer?

(2008) William J. Irvin et al.   EUROPEAN JOURNAL OF CANCER

A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens

(2008) Marlen Keimling et al.   INTERNATIONAL JOURNAL OF CANCER

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

(2007) Birgitte B Rasmussen et al.   LANCET ONCOLOGY